NCT Number: NCT00178165
Coordinating Center for Enhancing ADRD Caregiving
Established in 1995, Resources for Enhancing Alzheimer's Caregiver Health (REACH) is a unique, multi-site research program sponsored by the National Institute on Aging (NIA) and the National Institute on Nursing Research (NINR). The primary purpose of REACH is to carry out social and behavioral research on interventions designed to enhance family caregiving for Alzheimer's disease and related disorders. Specifically, REACH has two goals: to test the effectiveness of multiple different interventions and to evaluate the pooled effect of REACH interventions overall. REACH grew out of a National Institute of Health (NIH) initiative that acknowledged the well-documented burdens associated with family caregiving as well as the existence of promising family caregiver interventions reported in the literature.
Looking for future studies?
Notify MeKey information
Conditions
Age range
21 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
University of Alabama at Birmingham, Birmingham, Alabama, United States
About this study
Six sites (Boston, Birmingham, Memphis, Miami, Palo Alto, and Philadelphia) developed and evaluated a variety of multi-component interventions for family caregivers of persons with Alzheimer's Disease (AD) at the mild or moderate level of impairment. The multi-component interventions implemented across the six sites included: 1) Individual Information and Support strategies, 2) Group Support and Family Systems therapy, 3) Psychoeducational and Skill-based Training approaches, 4) Home-based Environmental interventions,, and 5) Enhanced Technology Support Systems. Although the interventions were derived from diverse theoretical models, they are all consistent with basic health-stress models in which the goal is to change the nature of specific stressors (e.g. problem behavior of the care recipient), their appraisal, and/or the caregivers response to the stressors. All of the REACH interventions were guided by detailed treatment manuals and certification procedures that assured that the interventions were delivered consistently over time at each site. Careful attention was also paid to the issue of treatment integrity. Different strategies were used at each site to induce and assess all three fundamental aspects of treatment integrity: delivery, receipt, and enactment (Burgio, et al., 2001). In addition, because the caregiving experience in race and ethnic minority families is particularly neglected in the field, there was a strong emphasis placed on the inclusion of African American and Hispanic caregivers. Thus, assessments as well as interventions were tailored at each site to meet the needs of culturally diverse racial/ethnic majority and minority populations.
All of the REACH sites shared several common goals, including: 1) designing theory-driven caregiving interventions to test hypotheses about intervention processes and their effect on family caregivers, 2) specifying intervention components that help us understand the pathways through which interventions produce desired outcomes, 3) developing a standardized outcome protocol to assess the impact of different strategies on caregivers and their care recipients within each site and across sites, and 4) creating a common database that would facilitate pooling data across sites. In addition, standard selection criteria were adopted by REACH.
Although REACH has some of the features of a traditional multi-site randomized controlled clinical trial (e.g., random assignment of participants to treatment and control conditions, common database and outcome measures, and identical measurement intervals across sites), it differs on one key dimension-the interventions varied across sites. REACH was designed to examine the feasibility and outcomes of multiple different intervention approaches, rather than to provide definitive information on the efficacy of one specific intervention strategy for enhancing caregiver outcomes. The strength of this approach is that it efficiently yields information about the effectiveness of different approaches to AD caregiving as well as the combined effects of active treatment versus controls, as reported in the planned meta-analysis.
REACH successfully randomized 1222 caregiver/care recipient dyads representing both majority and minority populations to 15 different conditions.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
CORE CARE RECIPIENT INCLUSION/EXCLUSION CRITERIA
Inclusion criteria
- NINCDS -ADRDA Criteria for Alzheimer's Disease and/or DSM IV Criteria for Alzheimer's Disease or other dementia or MMSE score < 23.
- Functional impairment: presence of two IADL or one ADL impairments.
Exclusion criteria
- Any terminal illness with life expectancy < 6 months
- Active treatment (chemotherapy, radiation therapy) for cancer
- More than three acute medical hospitalizations in past year (not for psychiatric or Alzheimer's Disease related admission)
- Schizophrenia (onset of delusions before age 45)
- Dementia secondary to head trauma (probable)
- Blindness or deafness if either disability prohibits them from completion of data collection or participation in the interventions
- MMSE = 0 and bedbound (confined to a bed or chair for > 22 hours per day, for at least 4 of the past 7 days)
- Planned nursing home admission in 6 months
CORE CAREGIVER INCLUSION/EXCLUSION CRITERIA
Inclusion criteria
- Age: 21 years and older
- Language: site specific, must be competent either orally or written
- Lives with care recipient
- Family member
- Gender: Palo Alto/Los Angeles will only enroll women. All other sites will enroll men and women
- Must have a telephone
- At enrollment, plan to remain in area for the duration of the intervention and follow-up
- Caregiver role of at least 6 months
- Provides > 4 hours of supervision or direct assistance per day for the care recipient
Exclusion criteria
- Any terminal illness with life expectancy < 6 months
- Active treatment (chemotherapy, radiation therapy) for cancer
- More than three acute medical hospitalizations in past year
- Involved in another clinical trial of interventions for caregivers (non drug study)
Second Level Review If the caregiver has been inconsistent with answers or repeated answers, then the interviewer will administer the SPMSQ. The interviewer will then discuss with the PI and coordinate another phone call with the caregiver.
If in the course of the telephone screen the research assistant believes that there may be difficulties for the caregiver regarding travel arrangements, hesitancy to answer questions, or other specific items (site-specific indications), the research assistant will refer to the PI for review.
All potential caregivers will receive a follow-up phone call for second level exclusion from the trial when appropriate.
Treatment and study plan
REACH for TLC (Telephone Linked Computer) system
ProcedurePrimary outcomes
-
The outcomes were assessed 6 months after randomization and included a measure of burden and a measure of depression. Caregiver burden was assessed using the Revised Memory and Behavior Problem Checklist (RMBPC).
-
Emotional distress was determined by the Center for Epidemiological Studies Depression Scale (CES-D) a global measure of depression.
Secondary outcomes
-
Long-term care placement of dementia patients and caregiver health and well-being
-
Use of cognitive enhancement medication
-
Clinical significance of caregiver interventions in diverse populations
Sponsors and collaborators
Lead sponsor
University of Pittsburgh
Other
Collaborators
- National Institute of Nursing Research (NINR)
- National Institute on Aging (NIA)
Registry information
Official study title
Coordinating Center for Enhancing Alzheimer Disease and Related Disorder Caregiving
Important dates
- Study start
- 1996
- Study completion
- 2001
- First posted
- Sep 15, 2005
- Registry last updated
- Sep 15, 2005
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Deprescribing in Patients Living With Dementia With Caregiver and Provider Nudges
NCT06347172
Alzheimer Disease, Brain Diseases
Boston, Massachusetts, United States
View Trial DetailsImpact of COVID-19 Vaccines on Cerebrovascular Health
NCT04992195
Alzheimer Disease, Arterial Thromboembolism
Hong Kong
View Trial DetailsCommunity-based Brain Health Program to Address Dementia Risk
NCT05529706
Alzheimer Disease, Brain Diseases
San Francisco, California, United States
View Trial DetailsBrain Safe: Consumer Intervention to Reduce Exposure to Drugs Linked to Alzheimer's Disease
NCT04121858
Alzheimer Disease, Brain Diseases
Indianapolis, Indiana, United States
View Trial Details